

# Jan K Damås

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9225194/publications.pdf>

Version: 2024-02-01

148  
papers

7,705  
citations

50276

46  
h-index

60623

81  
g-index

154  
all docs

154  
docs citations

154  
times ranked

12614  
citing authors

#	ARTICLE	IF	CITATIONS
1	Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. <i>Journal of Hepatology</i> , 2006, 44, 1167-1174.	3.7	493
2	Increased Expression of Visfatin in Macrophages of Human Unstable Carotid and Coronary Atherosclerosis. <i>Circulation</i> , 2007, 115, 972-980.	1.6	428
3	Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. <i>European Heart Journal</i> , 2016, 37, 2406-2413.	2.2	270
4	Systemic inflammation in heart failure – The whys and wherefores. <i>Heart Failure Reviews</i> , 2006, 11, 83-92.	3.9	252
5	Cholesterol Crystals Induce Complement-Dependent Inflammasome Activation and Cytokine Release. <i>Journal of Immunology</i> , 2014, 192, 2837-2845.	0.8	236
6	Enhanced T-Cell Expression of RANK Ligand in Acute Coronary Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 857-863.	2.4	170
7	Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1845-1855.	2.8	169
8	Chemokines and Cardiovascular Risk. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1909-1919.	2.4	161
9	Exercise reduces plasma levels of the chemokines MCP-1 and IL-8 in subjects with the metabolic syndrome. <i>European Heart Journal</i> , 2004, 25, 349-355.	2.2	151
10	Role of inflammation in the progression of heart failure. <i>Current Cardiology Reports</i> , 2007, 9, 236-241.	2.9	151
11	Elevated Levels of Activin A in Heart Failure. <i>Circulation</i> , 2004, 109, 1379-1385.	1.6	150
12	C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodeling following acute myocardial infarction. <i>European Heart Journal</i> , 2009, 30, 1180-1186.	2.2	143
13	Increased Expression of Interleukin-1 in Coronary Artery Disease With Downregulatory Effects of HMG-CoA Reductase Inhibitors. <i>Circulation</i> , 2004, 109, 1966-1972.	1.6	142
14	Inflammatory and anti-inflammatory cytokines in chronic heart failure: Potential therapeutic implications. <i>Annals of Medicine</i> , 2005, 37, 74-85.	3.8	140
15	Stromal Cell-Derived Factor-1 in Unstable Angina. <i>Circulation</i> , 2002, 106, 36-42.	1.6	139
16	Enhanced Expression of the Homeostatic Chemokines CCL19 and CCL21 in Clinical and Experimental Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 614-620.	2.4	134
17	Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2001, 37, 485-491.	2.8	128
18	Hepatitis C reinfection after sustained virological response. <i>Journal of Hepatology</i> , 2016, 64, 1020-1026.	3.7	122

#	ARTICLE	IF	CITATIONS
19	Expression of Fractalkine (CX3CL1) and its Receptor, CX3CR1, Is Elevated in Coronary Artery Disease and Is Reduced During Statin Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 2567-2572.	2.4	119
20	Whole Genome Gene Expression Meta-Analysis of Inflammatory Bowel Disease Colon Mucosa Demonstrates Lack of Major Differences between Crohn's Disease and Ulcerative Colitis. <i>PLoS ONE</i> , 2013, 8, e56818.	2.5	111
21	Interleukin-7 Mediated Inflammation in Unstable Angina. <i>Circulation</i> , 2003, 107, 2670-2676.	1.6	105
22	Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1460-1467.	2.8	99
23	Soluble CD40 Ligand in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2004, 110, 999-1005.	1.6	99
24	Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure modulatory effect of intravenous immunoglobulin. <i>Journal of the American College of Cardiology</i> , 2001, 38, 187-193.	2.8	93
25	Cardiometabolic Traits, Sepsis, and Severe COVID-19. <i>Circulation</i> , 2020, 142, 1791-1793.	1.6	93
26	Intracellular Nicotinamide Phosphoribosyltransferase Protects against Hepatocyte Apoptosis and Is Down-Regulated in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 3039-3047.	3.6	89
27	Neutrophil Gelatinase-Associated Lipocalin. <i>Chest</i> , 2010, 138, 888-895.	0.8	89
28	Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. <i>Cardiovascular Research</i> , 2002, 54, 175-182.	3.8	82
29	Interleukin-10 enhances the oxidized LDL-induced foam cell formation of macrophages by antiapoptotic mechanisms. <i>Journal of Lipid Research</i> , 2005, 46, 211-219.	4.2	78
30	Soluble CD40 ligand in acute and chronic heart failure. <i>European Heart Journal</i> , 2005, 26, 1101-1107.	2.2	71
31	Cytokine expression profiling of the myocardium reveals a role for CX3CL1 (fractalkine) in heart failure. <i>Journal of Molecular and Cellular Cardiology</i> , 2008, 45, 261-269.	1.9	69
32	Fecal neutrophil gelatinase-associated lipocalin as a biomarker for inflammatory bowel disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 128-135.	2.8	66
33	Enhanced Expression of CXCL10 in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 265-274.	1.9	62
34	Sensing of HIV-1 by TLR8 activates human T cells and reverses latency. <i>Nature Communications</i> , 2020, 11, 147.	12.8	62
35	8-Isoprostane increases expression of interleukin-8 in human macrophages through activation of mitogen-activated protein kinases. <i>Cardiovascular Research</i> , 2003, 59, 945-954.	3.8	60
36	The Impact of Infectious Disease Specialist Consultation for Staphylococcus aureus Bloodstream Infections: A Systematic Review. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw048.	0.9	60

#	ARTICLE	IF	CITATIONS
37	Early identification of sepsis in hospital inpatients by ward nurses increases 30-day survival. <i>Critical Care</i> , 2016, 20, 244.	5.8	60
38	Burden of bloodstream infection in an area of Mid-Norway 2002-2013: a prospective population-based observational study. <i>BMC Infectious Diseases</i> , 2017, 17, 205.	2.9	56
39	Enhanced Plasma Levels of LIGHT in Unstable Angina. <i>Circulation</i> , 2005, 112, 2121-2129.	1.6	55
40	Elevated levels of activin A in clinical and experimental pulmonary hypertension. <i>Journal of Applied Physiology</i> , 2009, 106, 1356-1364.	2.5	55
41	Epidemiology and outcome of <i>Staphylococcus aureus</i> bloodstream infection and sepsis in a Norwegian county 1996-2011: an observational study. <i>BMC Infectious Diseases</i> , 2015, 15, 116.	2.9	55
42	Abnormal interleukin-7 function in common variable immunodeficiency. <i>Blood</i> , 2005, 105, 2887-2890.	1.4	54
43	A Potential Role of the CXC Chemokine GRO $\alpha$ in Atherosclerosis and Plaque Destabilization. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1005-1011.	2.4	54
44	Lipocalin 2 Imparts Selective Pressure on Bacterial Growth in the Bladder and Is Elevated in Women with Urinary Tract Infection. <i>Journal of Immunology</i> , 2014, 193, 6081-6089.	0.8	54
45	Expression of CCL20 and Its Corresponding Receptor CCR6 Is Enhanced in Active Inflammatory Bowel Disease, and TLR3 Mediates CCL20 Expression in Colonic Epithelial Cells. <i>PLoS ONE</i> , 2015, 10, e0141710.	2.5	54
46	Potential anti-inflammatory role of activin A in acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2004, 44, 369-375.	2.8	53
47	Human Toll-like Receptor 8 (TLR8) Is an Important Sensor of Pyogenic Bacteria, and Is Attenuated by Cell Surface TLR Signaling. <i>Frontiers in Immunology</i> , 2019, 10, 1209.	4.8	49
48	Systemic Inflammation Persists the First Year after Mild Traumatic Brain Injury: Results from the Prospective Trondheim Mild Traumatic Brain Injury Study. <i>Journal of Neurotrauma</i> , 2020, 37, 2120-2130.	3.4	49
49	Associations of obesity and lifestyle with the risk and mortality of bloodstream infection in a general population: a 15-year follow-up of 64% individuals in the HUNT Study. <i>International Journal of Epidemiology</i> , 2017, 46, 1573-1581.	1.9	48
50	Increased Levels of Soluble CD40L in African Tick Bite Fever: Possible Involvement of TLRs in the Pathogenic Interaction between <i>Rickettsia africae</i> , Endothelial Cells, and Platelets. <i>Journal of Immunology</i> , 2006, 177, 2699-2706.	0.8	47
51	Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction. <i>Heart</i> , 2017, 103, 1521-1527.	2.9	46
52	High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins. <i>Cardiovascular Research</i> , 2008, 79, 195-203.	3.8	45
53	Cytokine Network in Scrub Typhus: High Levels of Interleukin-8 Are Associated with Disease Severity and Mortality. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2648.	3.0	45
54	Keap1 regulates inflammatory signaling in <i>Mycobacterium avium</i> -infected human macrophages. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E4272-80.	7.1	43

#	ARTICLE	IF	CITATIONS
55	N-3 PUFAs induce inflammatory tolerance by formation of KEAP1-containing SQSTM1/p62-bodies and activation of NFE2L2. <i>Autophagy</i> , 2017, 13, 1664-1678.	9.1	43
56	Monocyte chemoattractant protein-1 enhances and interleukin-10 suppresses the production of inflammatory cytokines in adult rat cardiomyocytes. <i>Basic Research in Cardiology</i> , 2001, 96, 345-352.	5.9	42
57	Cholesterol crystals use complement to increase NLRP3 signaling pathways in coronary and carotid atherosclerosis. <i>EBioMedicine</i> , 2020, 60, 102985.	6.1	41
58	Inflammation and chronic heart failureâ€™ potential therapeutic role of intravenous immunoglobulin. <i>Autoimmunity Reviews</i> , 2004, 3, 221-227.	5.8	38
59	Increased Production of CXCL16 in Experimental and Clinical Heart Failure. <i>Circulation: Heart Failure</i> , 2009, 2, 624-632.	3.9	38
60	Increased levels of CCR7 ligands in carotid atherosclerosis: different effects in macrophages and smooth muscle cells. <i>Cardiovascular Research</i> , 2014, 102, 148-156.	3.8	37
61	Agents targeting inflammation in heart failure. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 557-566.	4.1	35
62	Plasma levels of granzyme B are increased in patients with lipid-rich carotid plaques as determined by echogenicity. <i>Atherosclerosis</i> , 2007, 195, e142-e146.	0.8	35
63	Raised MCP-4 levels in symptomatic carotid atherosclerosis: an inflammatory link between platelet and monocyte activation. <i>Cardiovascular Research</i> , 2010, 86, 265-273.	3.8	35
64	Early anti-thrombotic and anti-inflammatory actions of statins and fibrates â€™ time for adjuvant therapy in acute coronary syndromes?. <i>Thrombosis and Haemostasis</i> , 2005, 94, 1-3.	3.4	34
65	Relative chemokine and adhesion molecule expression in Mediterranean spotted fever and African tick bite fever. <i>Journal of Infection</i> , 2009, 58, 68-75.	3.3	34
66	Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI). <i>Open Heart</i> , 2019, 6, e001108.	2.3	34
67	The Homeostatic Chemokine CCL21 Predicts Mortality and May Play a Pathogenic Role in Heart Failure. <i>PLoS ONE</i> , 2012, 7, e33038.	2.5	33
68	Cyclodextrin Reduces Cholesterol Crystalâ€™Induced Inflammation by Modulating Complement Activation. <i>Journal of Immunology</i> , 2017, 199, 2910-2920.	0.8	31
69	Increased expression of LIGHT/TNFSF14 and its receptors in experimental and clinical heart failureâ€™. <i>European Journal of Heart Failure</i> , 2008, 10, 352-359.	7.1	30
70	The role of intravenous immunoglobulin in the treatment of chronic heart failure. <i>International Journal of Cardiology</i> , 2006, 112, 40-45.	1.7	29
71	Chemokines in Children With Heterozygous Familial Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 200-205.	2.4	29
72	Mucosal Toll-like Receptor 3-dependent Synthesis of Complement Factor B and Systemic Complement Activation in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1.	1.9	29

#	ARTICLE	IF	CITATIONS
73	Toll-Like Receptor 8 Is a Major Sensor of Group B Streptococcus But Not Escherichia coli in Human Primary Monocytes and Macrophages. <i>Frontiers in Immunology</i> , 2017, 8, 1243.	4.8	29
74	Inflammatory Interaction Between LIGHT and Proteinase-Activated Receptor-2 in Endothelial Cells. <i>Circulation Research</i> , 2009, 104, 60-68.	4.5	28
75	Antiinflammatory Effects of Tetradecylthioacetic Acid Involve Both Peroxisome Proliferator-Activated Receptor $\alpha$ -Dependent and $\alpha$ -Independent Pathways. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 1364-1369.	2.4	27
76	IL-10 Enhances MD-2 and CD14 Expression in Monocytes and the Proteins Are Increased and Correlated in HIV-Infected Patients. <i>Journal of Immunology</i> , 2009, 182, 588-595.	0.8	27
77	Reconstituted High-Density Lipoprotein Attenuates Cholesterol Crystal-Induced Inflammatory Responses by Reducing Complement Activation. <i>Journal of Immunology</i> , 2015, 195, 257-264.	0.8	27
78	Association of iron status with the risk of bloodstream infections: results from the prospective population-based HUNT Study in Norway. <i>Intensive Care Medicine</i> , 2018, 44, 1276-1283.	8.2	27
79	Patients with Pulmonary Hypertension Related to Congenital Systemic-to-Pulmonary Shunts are Characterized by Inflammation Involving Endothelial Cell Activation and Platelet-mediated Inflammation. <i>Congenital Heart Disease</i> , 2009, 4, 153-159.	0.2	25
80	Epidemiology and outcome of sepsis in adult patients with Streptococcus pneumoniae infection in a Norwegian county 1993-2011: an observational study. <i>BMC Infectious Diseases</i> , 2016, 16, 223.	2.9	25
81	Trends in antimicrobial resistance and empiric antibiotic therapy of bloodstream infections at a general hospital in Mid-Norway: a prospective observational study. <i>BMC Infectious Diseases</i> , 2017, 17, 116.	2.9	25
82	Expression of neutrophil gelatinase-associated lipocalin (NGAL) in the gut in Crohn's disease. <i>Cell and Tissue Research</i> , 2018, 374, 339-348.	2.9	25
83	The complex role of T-cell-based immunity in atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2008, 10, 236-243.	4.8	24
84	Raised LIGHT Levels in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 202-207.	5.6	24
85	The tumour necrosis factor superfamily ligand APRIL (TNFSF13) is released upon platelet activation and expressed in atherosclerosis. <i>Thrombosis and Haemostasis</i> , 2009, 102, 704-710.	3.4	24
86	Circulating levels of HMGB1 are correlated strongly with MD2 in HIV-infection: Possible implication for TLR4-signalling and chronic immune activation. <i>Innate Immunity</i> , 2013, 19, 290-297.	2.4	22
87	Increased endothelial and macrophage markers are associated with disease severity and mortality in scrub typhus. <i>Journal of Infection</i> , 2014, 69, 462-469.	3.3	22
88	Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1 $\beta$ in non-ST-elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2018, 271, 1-7.	1.7	22
89	Chemokines in cardiovascular risk prediction. <i>Thrombosis and Haemostasis</i> , 2007, 97, 748-54.	3.4	22
90	Interleukin-6 inhibition in ST-elevation myocardial infarction: Immune cell profile in the randomised ASSAIL-MI trial. <i>EBioMedicine</i> , 2022, 80, 104013.	6.1	22

#	ARTICLE	IF	CITATIONS
91	Impaired Inhibitory Effect of Interleukin-10 on the Balance Between Matrix Metalloproteinase-9 and Its Inhibitor in Mononuclear Cells From Hyperhomocysteinemic Subjects. <i>Stroke</i> , 2006, 37, 1731-1736.	2.0	21
92	Soluble Markers of the Toll-Like Receptor 4 Pathway Differentiate between Active and Latent Tuberculosis and Are Associated with Treatment Responses. <i>PLoS ONE</i> , 2013, 8, e69896.	2.5	21
93	Circulating PCSK9 and Risk of Myocardial Infarction. <i>JACC Basic To Translational Science</i> , 2016, 1, 568-575.	4.1	21
94	IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction. <i>Frontiers in Immunology</i> , 2018, 9, 2035.	4.8	21
95	Effect of activated platelets on expression of cytokines in peripheral blood mononuclear cells – potential role of prostaglandin E2. <i>Thrombosis and Haemostasis</i> , 2004, 92, 1358-1367.	3.4	20
96	Platelet activation in heart transplant recipients. <i>Clinical Transplantation</i> , 2004, 18, 142-147.	1.6	20
97	Genetic variants in the DNA repair gene NEIL3 and the risk of myocardial infarction in a nested case-control study. <i>The HUNT Study. DNA Repair</i> , 2015, 28, 21-27.	2.8	20
98	Enhanced levels of the CCR7 ligands CCL19 and CCL21 in HIV infection: correlation with viral load, disease progression and response to highly active antiretroviral therapy. <i>Aids</i> , 2009, 23, 135-138.	2.2	19
99	Monitoring quality of care for peripheral intravenous catheters; feasibility and reliability of the peripheral intravenous catheters mini questionnaire (PVC-miniQ). <i>BMC Health Services Research</i> , 2019, 19, 636.	2.2	19
100	The inflammatory response is related to circulatory failure after out-of-hospital cardiac arrest: A prospective cohort study. <i>Resuscitation</i> , 2022, 170, 115-125.	3.0	19
101	Soluble CXCL16 and risk of myocardial infarction: The HUNT study in Norway. <i>Atherosclerosis</i> , 2016, 244, 188-194.	0.8	18
102	Anxiety and Depression Symptoms in a General Population and Future Risk of Bloodstream Infection: The HUNT Study. <i>Psychosomatic Medicine</i> , 2018, 80, 673-679.	2.0	18
103	Epidemiological and clinical characteristics of immunocompromised patients infected with <i>Pneumocystis jirovecii</i> in a twelve-year retrospective study from Norway. <i>BMC Infectious Diseases</i> , 2021, 21, 659.	2.9	18
104	Treatment with the PPAR $\gamma$ agonist rosiglitazone downregulates interleukin-1 receptor antagonist in individuals with metabolic syndrome. <i>European Journal of Endocrinology</i> , 2010, 162, 267-273.	3.7	17
105	Increased Serum Levels of LIGHT/TNFSF14 in Nonalcoholic Fatty Liver Disease: Possible Role in Hepatic Inflammation. <i>Clinical and Translational Gastroenterology</i> , 2015, 6, e95.	2.5	16
106	Novel Insights Into the Effects of Interleukin 6 Antagonism in Non-ST-Segment Elevation Myocardial Infarction Employing the SOMAscan Proteomics Platform. <i>Journal of the American Heart Association</i> , 2020, 9, e015628.	3.7	16
107	Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction. <i>Open Heart</i> , 2018, 5, e000765.	2.3	15
108	Body mass index and risk of dying from a bloodstream infection: A Mendelian randomization study. <i>PLoS Medicine</i> , 2020, 17, e1003413.	8.4	15

#	ARTICLE	IF	CITATIONS
109	A Complex Interaction between Rickettsia conorii and Dickkopf-1 – Potential Role in Immune Evasion Mechanisms in Endothelial Cells. PLoS ONE, 2012, 7, e43638.	2.5	15
110	Low levels of short- and medium-chain acylcarnitines in HIV-infected patients. European Journal of Clinical Investigation, 2016, 46, 408-417.	3.4	14
111	Extracellular matrix markers and risk of myocardial infarction: The HUNT Study in Norway. European Journal of Preventive Cardiology, 2017, 24, 1161-1167.	1.8	13
112	Immunomodulating Therapy: New Treatment Modality in Congestive Heart Failure. Congestive Heart Failure, 2003, 9, 64-69.	2.0	12
113	Therapeutic Potential of Anticytokine Therapy in Congestive Heart Failure. American Journal of Cardiovascular Drugs, 2004, 4, 169-177.	2.2	12
114	Inflammation in coronary artery disease: potential role for immunomodulatory therapy. Expert Review of Cardiovascular Therapy, 2005, 3, 1111-1124.	1.5	12
115	Chemokines and common variable immunodeficiency; possible contribution of the fractalkine system (CX3CL1/CX3CR1) to chronic inflammation. Clinical Immunology, 2009, 130, 151-161.	3.2	12
116	Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction. International Journal of Cardiology, 2019, 274, 348-350.	1.7	11
117	Variation in Serum PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9), Cardiovascular Disease Risk, and an Investigation of Potential Unanticipated Effects of PCSK9 Inhibition. Circulation Genomic and Precision Medicine, 2019, 12, e002335.	3.6	11
118	The Palliative Radiotherapy and Inflammation Study (PRAIS) - protocol for a longitudinal observational multicenter study on patients with cancer induced bone pain. BMC Palliative Care, 2018, 17, 110.	1.8	10
119	Explaining sex differences in risk of bloodstream infections using mediation analysis in the population-based HUNT study in Norway. Scientific Reports, 2022, 12, 8436.	3.3	10
120	T Cells in Coronary Artery Disease. Journal of the American College of Cardiology, 2007, 50, 1459-1461.	2.8	9
121	TLR8 and complement C5 induce cytokine release and thrombin activation in human whole blood challenged with Gram-positive bacteria. Journal of Leukocyte Biology, 2020, 107, 673-683.	3.3	9
122	Anti-inflammatory trials in chronic heart failure. Heart Failure Monitor, 2006, 5, 2-9.	0.7	9
123	Microbubbles in the Pulmonary Artery Generated During Experimental Hepatic Radiofrequency Ablation Is Correlated with Increased Pulmonary Arterial Pressure. Journal of Vascular and Interventional Radiology, 2007, 18, 437-442.	0.5	7
124	Transitions Between Circulatory States After Out-of-Hospital Cardiac Arrest: Protocol for an Observational, Prospective Cohort Study. JMIR Research Protocols, 2018, 7, e17.	1.0	6
125	Potential Mechanisms of Benefit with Thalidomide in Chronic Heart Failure. American Journal of Cardiovascular Drugs, 2007, 7, 127-134.	2.2	5
126	Effect of eptifibatide on platelet-mediated inflammation in acute coronary syndromes. International Journal of Cardiology, 2011, 151, 385-387.	1.7	4



#	ARTICLE	IF	CITATIONS
127	Monocyte/macrophage and T cell activation markers are not independently associated with MI risk in healthy individuals - results from the HUNT Study. <i>International Journal of Cardiology</i> , 2017, 243, 502-504.	1.7	4
128	Bronchial microdialysis monitoring of inflammatory response in open abdominal aortic aneurysm repair; an observational study. <i>Physiological Reports</i> , 2017, 5, e13348.	1.7	4
129	GWAS Identifies LINC01184/SLC12A2 as a Risk Locus for Skin and Soft Tissue Infections. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2083-2086.e8.	0.7	4
130	Potential role for immunomodulatory therapy in atherosclerotic plaque stabilisation. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2169-2180.	1.8	3
131	Systemic markers of inflammation “ are they useful predictive tools in coronary artery disease?. <i>Scandinavian Cardiovascular Journal</i> , 2006, 40, 262-266.	1.2	3
132	Genome-Wide Linkage Analysis of the Risk of Contracting a Bloodstream Infection in 47 Pedigrees Followed for 23 Years Assembled From a Population-Based Cohort (the HUNT Study)*. <i>Critical Care Medicine</i> , 2020, 48, 1580-1586.	0.9	3
133	Secreted Wnt antagonists in scrub typhus. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009185.	3.0	3
134	Atherosclerotic Plaque Stabilization - Potential Role for Immunomodulatory Therapy. <i>Vascular Disease Prevention</i> , 2004, 1, 17-31.	0.2	3
135	Hepatitis C outreach project and cross-sectional epidemiology in high-risk populations in Trondheim, Norway. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 2049936121110539.	1.8	3
136	Risk of lower respiratory tract infections: a genome-wide association study with Mendelian randomization analysis in three independent European populations. <i>Clinical Microbiology and Infection</i> , 2022, 28, 732.e1-732.e7.	6.0	2
137	Thyroid function and risk of bloodstream infections: Results from the Norwegian prospective population-based HUNT Study. <i>Clinical Endocrinology</i> , 2021, , .	2.4	2
138	Transcapillary fluid flux and inflammatory response during neonatal therapeutic hypothermia: an open, longitudinal, observational study. <i>BMC Pediatrics</i> , 2018, 18, 82.	1.7	1
139	The Role of <i>rs4957796</i> in the Risk of Developing and Dying from a Bloodstream Infection: A 23-Year Follow-up of the Population-based Nord-Trøndelag Health Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e297-e303.	5.8	1
140	Inflammatory Markers and Radiotherapy Response in Patients With Painful Bone Metastases. <i>Journal of Pain and Symptom Management</i> , 2022, 64, 330-339.	1.2	1
141	No Inflammatory Response Related to Pulmonary Hemodynamics in Children with Systemic to Pulmonary Shunts. <i>Congenital Heart Disease</i> , 2011, 6, 338-346.	0.2	0
142	Cyclodextrin inhibits CC-induced complement activation. <i>Molecular Immunology</i> , 2017, 89, 167-168.	2.2	0
143	Body mass index and risk of dying from a bloodstream infection: A Mendelian randomization study. , 2020, 17, e1003413.		0
144	Body mass index and risk of dying from a bloodstream infection: A Mendelian randomization study. , 2020, 17, e1003413.		0

#	ARTICLE	IF	CITATIONS
145	Body mass index and risk of dying from a bloodstream infection: A Mendelian randomization study. , 2020, 17, e1003413.		0
146	Body mass index and risk of dying from a bloodstream infection: A Mendelian randomization study. , 2020, 17, e1003413.		0
147	Body mass index and risk of dying from a bloodstream infection: A Mendelian randomization study. , 2020, 17, e1003413.		0
148	Body mass index and risk of dying from a bloodstream infection: A Mendelian randomization study. , 2020, 17, e1003413.		0